FDA Approves New Breast Cancer Pill After Hormone Therapy Stops Working
Summary
The FDA approved once-daily giredestrant with everolimus for certain people with advanced, estrogen-receptor-positive, HER2-negative breast cancer that worsened after hormone therapy. The approval covers tumors with ESR1 mutations, which can make hormone treatments less effective; a blood test can identify these mutations. In a clinical trial, the combination delayed cancer worsening compared with standard hormone therapy, but its effect on overall survival is not yet known.Key Facts
- The treatment combines giredestrant with everolimus.
- The approval applies to advanced ER-positive, HER2-negative breast cancer with ESR1 mutations that worsened after hormone therapy.
- The FDA also approved the FoundationOne Liquid CDx blood test to identify tumor DNA associated with ESR1 mutations.
- The trial included 373 adults, 207 of whom had ESR1 mutations.
- Among patients with ESR1 mutations, median time before cancer worsened was 10 months with giredestrant and everolimus, compared with 5.5 months with standard hormone therapy.
- Tumors shrank in 27 percent of patients receiving the combination and 14 percent receiving standard hormone therapy.
- The treatment’s effect on overall survival remains unknown.
- Reported adverse reactions included mouth or lung-tissue inflammation, rash, fatigue, diarrhea, musculoskeletal pain, and nausea; the label also warns about slow heartbeat and fetal harm.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.